Ipsen SA - Asset Resilience Ratio
Ipsen SA (IPN) has an Asset Resilience Ratio of 21.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IPN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how Ipsen SA's Asset Resilience Ratio has changed over time. See shareholders equity of Ipsen SA for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ipsen SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Ipsen SA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.45 Billion | 21.16% |
| Short-term Investments | €32.30 Million | 0.47% |
| Total Liquid Assets | €1.48 Billion | 21.63% |
Asset Resilience Insights
- Good Liquidity Position: Ipsen SA maintains a healthy 21.63% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ipsen SA Industry Peers by Asset Resilience Ratio
Compare Ipsen SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Ipsen SA (2002–2024)
The table below shows the annual Asset Resilience Ratio data for Ipsen SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.02% | €1.10 Million ≈ $1.29 Million |
€6.44 Billion ≈ $7.53 Billion |
-0.15pp |
| 2023-12-31 | 0.17% | €10.60 Million ≈ $12.39 Million |
€6.32 Billion ≈ $7.39 Billion |
-21.24pp |
| 2022-12-31 | 21.40% | €1.20 Billion ≈ $1.40 Billion |
€5.61 Billion ≈ $6.56 Billion |
+4.23pp |
| 2021-12-31 | 17.17% | €857.10 Million ≈ $1.00 Billion |
€4.99 Billion ≈ $5.83 Billion |
+16.55pp |
| 2020-12-31 | 0.62% | €26.80 Million ≈ $31.33 Million |
€4.31 Billion ≈ $5.04 Billion |
-3.96pp |
| 2019-12-31 | 4.58% | €197.20 Million ≈ $230.55 Million |
€4.31 Billion ≈ $5.04 Billion |
-1.57pp |
| 2018-12-31 | 6.15% | €207.70 Million ≈ $242.82 Million |
€3.38 Billion ≈ $3.95 Billion |
-2.98pp |
| 2017-12-31 | 9.13% | €280.60 Million ≈ $328.05 Million |
€3.07 Billion ≈ $3.59 Billion |
-5.91pp |
| 2016-12-31 | 15.04% | €364.50 Million ≈ $426.14 Million |
€2.42 Billion ≈ $2.83 Billion |
+14.69pp |
| 2015-12-31 | 0.35% | €6.80 Million ≈ $7.95 Million |
€1.94 Billion ≈ $2.27 Billion |
+0.35pp |
| 2014-12-31 | 0.01% | €100.00K ≈ $116.91K |
€1.71 Billion ≈ $2.00 Billion |
-0.01pp |
| 2013-12-31 | 0.01% | €200.00K ≈ $233.82K |
€1.57 Billion ≈ $1.83 Billion |
-0.02pp |
| 2012-12-31 | 0.03% | €516.00K ≈ $603.26K |
€1.56 Billion ≈ $1.83 Billion |
+0.03pp |
| 2011-12-31 | 0.00% | €9.00K ≈ $10.52K |
€1.63 Billion ≈ $1.91 Billion |
0.00pp |
| 2010-12-31 | 0.00% | €49.00K ≈ $57.29K |
€1.68 Billion ≈ $1.96 Billion |
-0.07pp |
| 2009-12-31 | 0.07% | €1.16 Million ≈ $1.36 Million |
€1.58 Billion ≈ $1.84 Billion |
-0.09pp |
| 2008-12-31 | 0.16% | €2.53 Million ≈ $2.96 Million |
€1.57 Billion ≈ $1.84 Billion |
-0.30pp |
| 2007-12-31 | 0.46% | €6.10 Million ≈ $7.13 Million |
€1.32 Billion ≈ $1.55 Billion |
+0.39pp |
| 2006-12-31 | 0.07% | €901.00K ≈ $1.05 Million |
€1.21 Billion ≈ $1.42 Billion |
+0.07pp |
| 2005-12-31 | 0.00% | €18.00K ≈ $21.04K |
€942.51 Million ≈ $1.10 Billion |
-11.71pp |
| 2004-12-31 | 11.71% | €72.59 Million ≈ $84.86 Million |
€619.71 Million ≈ $724.51 Million |
-1.40pp |
| 2003-12-31 | 13.12% | €87.34 Million ≈ $102.11 Million |
€665.90 Million ≈ $778.50 Million |
-3.85pp |
| 2002-12-31 | 16.97% | €112.39 Million ≈ $131.39 Million |
€662.33 Million ≈ $774.34 Million |
-- |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more